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In 2007, FTO was identified as the first genome-wide association study (GWAS) gene associated with obesity in humans. Since
then, various animal models have served to establish the mechanistic basis behind this association. Many earlier studies focussed
on FTO’s effects on food intake via central mechanisms. Emerging evidence, however, implicates adipose tissue development and
function in the causal relationship between perturbations in FTO expression and obesity.The purpose of this mini review is to shed
light on these new studies of FTO function in adipose tissue and present a clearer picture of its impact on obesity susceptibility.
1. Introduction
Obesity has risen to become the major health crisis of the
current and potentially future generations. The latest figures
from the World Health Organization (WHO) reveal a global
estimate of 1.4 billion overweight individuals [1]. Most trou-
bling is the devastating socioeconomic impact of obesity and
related metabolic disturbances [2]. The WHO has estimated
that 2–7% of global spending on health care is driven by a
high body mass index (BMI) [3]. One such example is the
financial strain being applied to the UK’s National Health
Service by obesity [4]. It is clear that more effective strategies
are required, in terms of public policy, medical treatment,
and biomedical research, to provide financially sustainable
health care to be able to deal with the obesity crisis head-
on. In recent years, genome-wide association studies (GWAS)
have offered renewed promise in the quest to understand the
genetics of obesity which has for too long eluded modern
science.
In 2007, several independent GWAS and population
based approaches identified associations between SNPs in
intron 1 of FTO and human obesity in various European
populations [5–8]. Since then, many studies have confirmed
the association between SNPs in intron 1 of FTO and BMI in
non-European populations, notable East Asians [9–11], South
Asians [12–16], Africans [17], Hispanics [18, 19], and Native
Americans [20], clearly demonstrating that the influence
of FTO SNPs on obesity is a global trend. No association
has been found between these obesity-associated SNPs and
FTO expression levels in adipose tissue [21–25]. The fact
that the obesity-associated FTO SNPs are intronic has led
to the notion that the SNPs may affect obesity through
influencing the expression of genes proximal to FTO in
the locus, namely, RPGRIP1L, IRX3, and IRX5 [26–29]. The
obesity-associated allele of SNP rs8051036 has been suggested
to decrease RPGRIP1L expression via reduced affinity for a
transcriptional activator [26]. IRX3 expression has recently
been documented to account for the obesity association
with FTO SNPs in human cerebellar tissue [28] and in the
pancreas in zebrafish [30]. Furthermore, long-range func-
tional connections were observed between enhancers within
the obesity-associated Fto interval and Irx3 expression (and
not Fto) in adult mouse brain tissues [28]. Another recent
study found that an obesity-associated SNP in intron 1 of
FTO was located in a long enhancer region in preadipocytes
specifically. The risk allele disrupted the binding of the
gene regulator ARID5b, which in turn leads to increased
expression of IRX3 and IRX5 in preadipocytes [29].
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These studies indicate that the obesity-associated region
in intron 1 is likely to regulate the expression of various genes,
which might be tissue- and developmental stage-specific.
Future studies will address how the obesity-associated SNPs
contribute to increased adiposity in other tissues and at early
developmental stages. Thus, it remains a possibility that the
obesity associated with the SNP is mediated by FTO during
development or in peripheral tissues. As FTOwas considered
the “obesity-gene” in 2007 when the first GWAS papers
were published, many research groups sought out to examine
FTO’s role in the regulation of body weight. Regardless of
whether the obesity-associated SNP affects FTO expression
levels, these studies have clearly proven an important role of
FTO in the regulation of body weight, independent of IRX3,
IRX5, and RPGRIP1L.
One important peripheral tissue that has increasingly
been shown to be consequential to metabolic regulation and
obesity susceptibility is adipose tissue. Interestingly, while it
has been long established that FTO is highly expressed in
adipose tissues [5], its function remained largely obscured.
The purpose of this review is to examine the emerging
role of FTO in adipose tissue and its relevance to obesity
susceptibility.
2. Mouse Models of FTO Function
The first murine model of global germline Fto loss was
described by Fischer et al. in 2009 [31]. Fto deficient mice
exhibited high perinatal lethality as well as postnatal growth
retardation. Furthermore, Fto deficient mice had reduced
lean and fat mass with respect to wild type mice. Intriguingly,
fat mass was progressively reduced over the time in Fto
deficient mice, to the extent that by 15 months of age Fto
deficient mice were almost totally void of gonadal white
adipose tissue (gWAT). Fischer and colleagues demonstrated
that Fto deficiency causes relatively increased food intake
as well as energy expenditure, potentially due to enhanced
sympathetic tone resulting from elevated serumnoradrenalin
levels. The effect on energy expenditure in Fto deficient
mice might have been due to the way in which the data
were corrected to lean mass [32]. Others did not find an
increase in energy expenditure in Fto deficient mice [33].
Interestingly, a model in which a point mutation in Fto
resulted in reduced FTO protein expression and catalytic
activity resulted in reduced lean mass and fat mass without
any effects on perinatal lethality [34]. Paradoxically, adult
onset Fto deficiency in mice (6 weeks of age) resulted in
increased adiposity compared to wild type mice, with no
effects on lean mass [33]. In line with these findings, a recent
study reported increased body weight and adiposity of Fto
knockout mice compared to wild type mice in response to
a high fat diet [35].
To compound the inconsistency in body composition
phenotypes with Fto deficiency, neural knockout of Fto led
to a reduction in body weight accompanied by a decrease in
lean mass, not fat mass [36], reflecting some of the germline
FTO-KO models. However, adult onset knockout of Fto in
the mediobasal hypothalamus decreased body weight with-
out affecting body composition [33].
Fto overexpression models appear to be more consis-
tent in describing an enhanced adiposity in Fto overex-
pression compared to wild type mice, an effect which is
most pronounced on a high fat diet. Church and colleagues
documented that Fto overexpression is accompanied by
increased gWAT mass and increased adipocyte size [37],
while Merkestein et al. revealed that adipocyte hypertrophy
is preceded by increased gWAT hyperplasia in response to
HFD, with respect to wild type mice demonstrating that
FTO influences adipogenesis [38]. Conversely, Fto deficient
mice have been shown to have reduced adipocyte size, both
under chow conditions [31] and in response to high fat diet
[39]; however, effects on adipose tissue hyperplasia were not
studied in these models.
Although many questions remain to be answered and a
clear understanding of the effects of FTO on body composi-
tion remains to be established, it is beyond doubt that FTO
exerts an influence over adiposity and it is plausible that FTO
directly regulates adipocyte development and metabolism.
3. Regulation of FTO Expression
The expression of FTO in adipose tissue is likely regulated in
various ways. There is ample evidence for crosstalk between
FTO and the LepRb-STAT3 signalling pathway and the
involvement of the p110 isoform of the CUX1 transcription
factor.
FTO risk alleles have been associated with changes in
circulating levels of the appetite regulating hormones leptin
and ghrelin. Several papers have shown that FTO risk allele
is associated with increased circulating leptin levels [40–
47]. However, this association appears to be mediated via
increased adiposity, as in several studies the association
disappears when correcting for BMI [42, 44–46]. Another
study reported an association of an FTO risk allele with a
decrease in circulating leptin levels which was independent
of BMI in older participants [48]. Carriers of FTO risk alleles
have been shown to have a reduced postprandial suppression
of circulating acyl-ghrelin levels [49]. Similarly, another study
found increased plasma ghrelin levels after overnight fast in
people with FTO risk alleles [48].
Leptin increased FTO expression in cardiomyocytes,
which was dependent on LepRb-STAT3 signalling and a
subsequent increase in the p110 CUX1 isoform [50]. Overex-
pression of FTO in the arcuate nucleus of the hypothalamus
in rats resulted in an increase in STAT3 mRNA [51]. On the
other hand, leptin activated the STAT3 signalling pathway
and reduced FTO expression in the arcuate nucleus, which
was dependent on the LepRb receptor [52]. In hepatocytes,
leptin administration, LepRb overexpression, and activation
of the STAT3 pathway with IL6 induced FTO protein expres-
sion, whereas knockdown of STAT3 inhibited leptin-induced
FTO mRNA expression. Conversely, overexpression of FTO
reduced leptin-induced STAT3 phosphorylation and affected
downstream events of this signalling pathway. Furthermore,
overexpressing of Fto in vivo in mouse livers affected STAT3
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phosphorylation and its downstream effects in a similar way
[53].
Further evidence of the crosstalk between leptin and FTO
comes from animal studies. In response to HFD, Fto deficient
mice did not develop leptin resistance, whereas wild type
mice did [35]. Furthermore, knocking out Fto improved the
features of the metabolic syndrome normally observed in
leptin deficient ob/ob mice [54].
Intron 1 of the FTO gene contains a binding site for the
p110 isoform of the CUX1 transcription factor. The obesity-
associated rs8050136 SNP is located in this region. Binding
of the p110 CUX1 isoform enhances FTO expression [26].
Therefore, this transcription factor is likely to regulate FTO
expression.
The FTO promoter region has also been shown to
contain a C/EBP𝛼 binding site and C/EBP𝛼 promoted FTO
expression in HEK293 and HeLa cells [55]. Furthermore,
miR-33 was shown to regulate FTO expression. miR-33 is
transcribed from an intronic region within SREBF2. SREBF2
is a transcriptional activator of many genes involved in the
synthesis and uptake of cholesterol, triglycerides, fatty acids,
and phospholipids. miR-33 is expressed inmany tissues in the
chicken, including adipose tissue. Knocking down miR-33 in
primary chicken hepatocytes increased the expression ofFTO
[56].
4. FTO and Adipogenesis
Several studies have examined the expression of FTO during
adipogenesis, the process by which new adipocytes are
formed from preadipocytes, which in turn derive from mes-
enchymal stem cells. This process which has been well docu-
mented in vitro occurs in 7–10 days. In cultured preadipocytes
and MEFs, Fto has been consistently shown to be highly
expressed in the early phase of adipogenesis and to decline
during the course of adipogenesis in vitro [24, 57–59].
These studies indicated a role for FTO in the adipogenic
process. Indeed, knockdown of Fto decreased adipogenesis in
3T3-L1 preadipocytes [58, 60] and in porcine preadipocytes
[61]. MEFs from Fto-KO mice exhibited reduced adipogenic
potential, whereas overexpression of Fto led to an enhanced
adipogenic program in primarymurine preadipocytes, 3T3L1
preadipocytes, and porcine preadipocytes [38, 60, 61].
In line with these findings, gonadal WAT from Fto
overexpressing mice fed a high fat diet for 8 weeks from
weaning contained an increased number of adipocytes com-
pared with WT mice; however, no differences in adipocyte
number were evident between Fto overexpression mice and
WT mice at weaning, clearly demonstrating that FTO pro-
motes obesogenic adipogenesis in adulthood but plays no
role in developmental adipogenesis [38]. This is important
as obesogenic adipogenesis, which occurs in response to
HFD in adulthood, has recently been shown to operate via
distinct signalling mechanisms and requiring different sub-
populations of preadipocytes [62]. Notably, the AKT2/PI3K
signalling pathway has been evidenced to be essential for
obesogenic adipogenesis but not required for developmen-
tal adipogenesis, possibly alluding to the insulin signalling
aspect of obesogenic adipogenesis which is clearly dependent
on dietary factors, in contrast to developmental adipogenesis
which responds to developmental cues that predominate
during organogenesis [62].
4.1. Catalytic Activity of FTO Necessary for Its Role in Adipo-
genesis. FTO is 2-oxoglutarate dependent demethylase of
single stranded nucleic acids [63]. Its main substrate is
likely 6-methyladenosine (m6A) in RNA [64]. In 3T3L1
preadipocytes, overexpression of full length wild type Fto
enhanced adipogenesis whereas overexpression of catalyt-
ically inactive R96Q Fto did not affect adipogenesis [60].
Similarly, the effect of Fto knockdown on adipogenesis in
3T3-L1 cells could be rescued by reexpressing wild type
Fto, but not by reexpressing catalytic inactive Fto [58]. The
reduction in cellular proliferation during the mitotic clonal
expansion phase of adipogenesis in Fto-KO MEFs could be
rescued by expressing WT Fto, but not by catalytic inactive
R313A Fto [38].
In porcine adipocytes, overexpression of FTO increased
m6A levels, and knockdown of FTO reduced these levels.
Interestingly, overexpression of the m6AmethylaseMETTL3
induced similar effects of FTO knockdown, whereas knock-
down of METTL3 had no effect. Chemically increasing
(via methyl donor betaine) m6A levels mimicked FTO
knockdown, whereas chemical reduction of m6A levels (via
methylation inhibitor cycloleucine) reflected the effects seen
with FTO overexpression [61]. In another study, knockdown
of ALKBH5, another m6A demethylase, did not affect adipo-
genesis. Knockdown ofMETTL3 on the other hand increased
lipid accumulation during adipogenesis [58]. So, m6A is
likely to play a role in adipogenesis, but the effect is substrate-
specific, as FTO’s catalytic activity is essential for adipogene-
sis; however, that of ALKBH5 is unlikely to be important.
4.2. Mechanism via Which FTO Affects Adipogenesis. FTO
was shown to influence adipogenesis at an early stage indeed,
during mitotic clonal expansion, which takes place during
the first 48 hours after adipogenic stimulation in vitro [38]. A
potentialmechanismviawhich FTO regulates adipogenesis is
RUNX1T1.The SRproteins are important for splice site recog-
nition and intron processing, and FTOwas shown to regulate
the splicing of SRFS2 target genes via modification of m6A
levels. One of these target genes is RUNX1T1, which has 2 iso-
forms. The short isoform is proadipogenic, whereas the long
isoform reduces adipogenesis. FTOknockdowndecreases the
expression of the short isoform [58]. RUNX1T1 has been
shown to regulate C/EBP𝛽 activity [65]. Interestingly enough,
FTO was shown to act as a transcriptional coactivator for
the transcriptional regulators C/EBP𝛼, C/EBP𝛽, and C/EBP𝛿
[66]. One study found that FTO deficiency did not affect
the expression levels of C/EBP𝛽, suggesting FTO acts via a
C/EBP𝛽 independent route [39]. But FTO is likely to affect
the activity of C/EBP𝛽, rather than its expression.
5. FTO and Lipogenesis
Besides adipogenesis, FTOmight play a role in lipogenesis. In
one study, knocking down FTO in the human preadipocyte
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SGBS cells did not affect adipogenic differentiation, lipolysis,
or glucose uptake but did attenuate de novo lipogenesis [67].
And in human myotubes, FTO overexpression caused an
increase in lipogenesis and upregulation of the expression
of genes involved in lipogenesis [57]. Church and colleagues
reported a gross increase in adipocyte size after prolonged
high fat diet feeding in mice [37], and as adipogenesis also
relies upon lipogenesis to assemble lipids into triglycerides
during terminal differentiation, these findings suggest that
FTO may play two distinct roles in adipogenesis (during
MCE at the start and in lipid filling at the culmination of the
process). A recent study showed a link between lipogenesis
and adipogenesis via the carbohydrate-response element-
binding protein (chREBP) which was shown to regulate
PPAR𝛾 [68]. It is conceivable that FTOmay influence chREBP
and it would be interesting to assess the effects on chREBP
expression in preadipocytes and MEFs from Fto-KO and Fto
overexpression mice.
6. FTO Deficiency and Browning of
White Adipose Tissue
An obesity-associated SNP in intron 1 of FTO has been
associated with decreased browning of white adipose tissue,
which coincided with an increase in expression of IRX3
and IRX5 in preadipocytes [29]. Browning of WAT has also
been reported in Irx3-KO mice [28]. Furthermore, also Fto-
KO mice showed signs of WAT browning. Expression of
Ucp1 in gonadal and inguinal fat pads was increased in Fto-
KO mice, and Fto deficient adipocytes showed increased
expression of Ucp1 and increased mitochondrial respiration
[67]. Furthermore, FTO variants were suggested to influence
adipose tissue lipolysis and metabolism [24, 46]. Given that
Fto deficiency is associated with increased circulating nora-
drenaline levels [31, 34, 67], increased thermogenic capacity
and lipolysis of Fto deficient adipocytes may result from
increased adrenergic receptor activation.
7. FTO and Developmental Programming
Given that Fto deficiency results in developmental abnor-
malities consistent with postnatal growth retardation [31],
characterized by reduced leanmass and body length, it would
be appropriate to postulate that FTO may act developmen-
tally to influence body composition. Interestingly, Dina and
colleagues demonstrated that FTO SNPs are associated not
only with adult obesity but also with childhood obesity [8].
In fact, the association between FTO SNPs and obesity peaks
during early adolescence and tapers off thereafter [45, 69–71],
suggesting that FTO SNPs may impact obesity by influencing
events during the developmental period. Interestingly, one
study found that the FTO risk allele is actually associated with
a reduction in BMI under the age of 2.5 years, and with a
shift in the timing of the BMI adiposity rebound, which is a
developmental marker. The obesity risk alleles accelerate the
developmental age, which subsequently results in an increase
in BMI during later time-points [71].
A recent study in rats found that FTOmRNA expression
in the hypothalamus was increased in offspring following
maternal obesity and was associated with a predisposition to
high fat diet induced obesity in adulthood, potentially due
to increased food intake [72]. It remains to be elucidated
whether a similar expression pattern is observed with mater-
nal obesity in offspring adipose tissue, although maternal
nutrient restriction had no impact on offspring adipose tissue
mRNA levels [73]. Epigenetic processes have been shown
to be highly active during the developmental period and
may represent a mechanism independent of changes in the
DNA sequence by which maternal diet may impact offspring
obesity susceptibility. Interestingly, FTO risk allele rs8050136
has been shown to have increased methylation on a per-allele
basis [74]. This could represent an exciting new mechanism
by which FTO SNPs affect obesity and warrants further
investigation. Furthermore, a very recent study observed a
parent-of-origin effect of FTO SNPs, albeit in a very small
population in Germany, suggesting that these parent-of-
origin effects may modulate the association between FTO
SNPs and obesity [75].
Recently, it was shown that adipogenesis during devel-
opment and obesity are regulated by distinct signalling
pathways and utilize separate preadipocyte populations (both
of which are marked by birth) [62]. Adulthood adipogenesis
in mice, which only occurs under HFD conditions, requires
Akt2/PI3K signalling and requires smooth muscle actin
(SMA) positive preadipocytes, whereas developmental adi-
pogenesis (organogenesis) is not dependent on this pathway
[62]. To this end, we have shown that Fto overexpression
does not affect developmental adipogenesis but has profound
effects on obesogenic adipogenesis [38]. Interestingly, in
endometrial cancer cells, 𝛽-estradiol- (E2-) induced prolif-
eration and invasion were shown to be mediated by FTO.
E2 stimulated FTO expression via the PI3K/Akt and MAPK
signalling pathways. FTO knockdown attenuated cancer cell
growth and proliferation which was mediated via cyclin D1
regulation [76]. This is particularly intriguing as FTO has
been shown to induce adipogenesis through augmenting
cyclin D1 expression during the MCE phase [38]. These
studies thus indicate that AKT/PI3K signalling may be a
crucial part of the as yet unidentified signalling process of
FTO-mediated adipogenesis; however, more direct evidence
is required to confirm this hypothesis.
8. Conclusion
Whether or not alterations in FTO expression are responsible
for the obesity-associated SNPs in intron 1 of FTO remains to
be unequivocally answered. Nevertheless, FTO clearly plays
an important role in adipogenesis. Given the similarities
between Fto and Irx3 animal models, these genes might act
well in concert to regulate adipogenesis and the occurrence
of browning of white adipose tissue. The discovery of FTO
as a demethylase of single stranded DNA and RNA, and its
target m6A, has revealed the importance of m6A in RNA and
how it is crucial for important physiological processes, such
as adipogenesis. Future studies will address the differences
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between FTO’s roles in development and in adulthood, not
only in adipose tissue but also in other tissues.
Conflict of Interests
The authors declare no conflict of interests.
References
[1] V. S. Malik, W. C. Willett, and F. B. Hu, “Global obesity:
trends, risk factors and policy implications,” Nature Reviews
Endocrinology, vol. 9, no. 1, pp. 13–27, 2013.
[2] A. H. Anis, W. Zhang, N. Bansback, D. P. Guh, Z. Amarsi,
and C. L. Birmingham, “Obesity and overweight in Canada: an
updated cost-of-illness study,”Obesity Reviews, vol. 11, no. 1, pp.
31–40, 2010.
[3] McKinsey Global Institute, Overcoming Obesity: An Initial
Economic Analysis, McKinsey Global Institute, 2014.
[4] S. Allender and M. Rayner, “The burden of overweight and
obesity-related ill health in the UK,” Obesity Reviews, vol. 8, no.
5, pp. 467–473, 2007.
[5] T. M. Frayling, N. J. Timpson, M. N.Weedon et al., “A common
variant in the FTO gene is associated with body mass index and
predisposes to childhood and adult obesity,” Science, vol. 316,
no. 5826, pp. 889–894, 2007.
[6] A. Scuteri, S. Sanna, W.-M. Chen et al., “Genome-wide associa-
tion scan shows genetic variants in the FTO gene are associated
with obesity-related traits,” PLoS Genetics, vol. 3, no. 7, article
e115, 2007.
[7] A. Hinney, T. T. Nguyen, A. Scherag et al., “Genome Wide
Association (GWA) study for early onset extreme obesity
supports the role of fat mass and obesity associated gene (FTO)
variants,” PLoS ONE, vol. 2, no. 12, Article ID e1361, 2007.
[8] C. Dina, D. Meyre, S. Gallina et al., “Variation in FTO con-
tributes to childhood obesity and severe adult obesity,” Nature
Genetics, vol. 39, no. 6, pp. 724–726, 2007.
[9] Y. S. Cho, M. J. Go, Y. J. Kim et al., “A large-scale genome-wide
association study of Asian populations uncovers genetic factors
influencing eight quantitative traits,”NatureGenetics, vol. 41, no.
5, pp. 527–534, 2009.
[10] W. Wen, Y.-S. Cho, W. Zheng et al., “Meta-analysis identifies
common variants associated with body mass index in east
Asians,” Nature Genetics, vol. 44, no. 3, pp. 307–311, 2012.
[11] Y. Okada, M. Kubo, H. Ohmiya et al., “Common variants at
CDKAL1 and KLF9 are associated with body mass index in east
Asian populations,”Nature Genetics, vol. 44, no. 3, pp. 302–306,
2012.
[12] S. D. Rees, M. Islam, M. Z. I. Hydrie et al., “An FTO variant
is associated with Type 2 diabetes in South Asian populations
after accounting for body mass index and waist circumference,”
Diabetic Medicine, vol. 28, no. 6, pp. 673–680, 2011.
[13] C. S. Yajnik, C. S. Janipalli, S. Bhaskar et al., “FTO gene variants
are strongly associated with type 2 diabetes in South Asian
Indians,” Diabetologia, vol. 52, no. 2, pp. 247–252, 2009.
[14] K. Ramya, V. Radha, S. Ghosh, P. P. Majumder, and V. Mohan,
“Genetic variations in the FTO gene are associated with type
2 diabetes and obesity in South Indians (CURES-79),” Diabetes
Technology andTherapeutics, vol. 13, no. 1, pp. 33–42, 2011.
[15] S. C. Moore, M. J. Gunter, C. R. Daniel et al., “Common genetic
variants and central adiposity among Asian-Indians,” Obesity,
vol. 20, no. 9, pp. 1902–1908, 2012.
[16] S. K. Vasan, T. Fall, M. J. Neville et al., “Associations of variants
in FTO and near MC4R with obesity traits in south Asian
Indians,” Obesity, vol. 20, no. 11, pp. 2268–2277, 2012.
[17] K. L. Monda, G. K. Chen, K. C. Taylor et al., “A meta-
analysis identifies new loci associated with body mass index in
individuals of African ancestry,” Nature Genetics, vol. 45, no. 6,
pp. 690–696, 2013.
[18] M.Villalobos-Compara´n,M. Teresa Flores-Dorantes,M. Teresa
Villarreal-Molina et al., “The FTO gene is associated with
adulthood obesity in the Mexican population,” Obesity, vol. 16,
no. 10, pp. 2296–2301, 2008.
[19] C. Dong, A. Beecham, S. Slifer et al., “Genome-wide linkage
and peak-wide association study of obesity-related quantitative
traits in Caribbean Hispanics,” Human Genetics, vol. 129, no. 2,
pp. 209–219, 2011.
[20] R. Rong, R. L. Hanson, D. Ortiz et al., “Association analysis
of variation in/near FTO, CDKAL1, SLC30A8, HHEX, EXT2,
IGF2BP2, LOC387761, and CDKN2B with type 2 diabetes and
related quantitative traits in Pima Indians,”Diabetes, vol. 58, no.
2, pp. 478–488, 2009.
[21] C. Zabena, J. L. Gonza´lez-Sa´nchez, M. T. Mart´ınez-Larrad et
al., “The FTO obesity gene. Genotyping and gene expression
analysis inmorbidly obese patients,”Obesity Surgery, vol. 19, no.
1, pp. 87–95, 2009.
[22] T. Lappalainen, M. Kolehmainen, U. Schwab et al., “Gene
expression of FTO in human subcutaneous adipose tissue,
peripheral blood mononuclear cells and adipocyte cell line,”
Journal of Nutrigenetics and Nutrigenomics, vol. 3, no. 1, pp. 37–
45, 2010.
[23] L. G. Grunnet, E. Nilsson, C. Ling et al., “Regulation and
function of FTO mRNA expression in human skeletal muscle
and subcutaneous adipose tissue,” Diabetes, vol. 58, no. 10, pp.
2402–2408, 2009.
[24] K.Wa˚hle´n, E. Sjo¨lin, and J. Hoffstedt, “The common rs9939609
gene variant of the fat mass- and obesity-associated gene FTO
is related to fat cell lipolysis,” Journal of Lipid Research, vol. 49,
no. 3, pp. 607–611, 2008.
[25] N. Klo¨ting, D. Schleinitz, K. Ruschke et al., “Inverse relationship
between obesity and FTO gene expression in visceral adipose
tissue in humans,”Diabetologia, vol. 51, no. 4, pp. 641–647, 2008.
[26] G. Stratigopoulos, C. A. LeDuc, M. L. Cremona, W. K. Chung,
andR. L. Leibel, “Cut-like homeobox 1 (CUX1) regulates expres-
sion of the fatmass and obesity-associated and retinitis pigmen-
tosa GTPase regulator-interacting protein-1-like (RPGRIP1L)
genes and coordinates leptin receptor signaling,”The Journal of
Biological Chemistry, vol. 286, no. 3, pp. 2155–2170, 2011.
[27] G. Stratigopoulos, J. F. M. Carli, D. R. O’Day et al., “Hypomor-
phism for RPGRIP1L, a ciliary gene vicinal to the fto locus,
causes increased adiposity in mice,” Cell Metabolism, vol. 19, no.
5, pp. 767–779, 2014.
[28] S. Smemo, J. J. Tena, K.-H. Kim et al., “Obesity-associated
variants within FTO form long-range functional connections
with IRX3,” Nature, vol. 507, no. 7492, pp. 371–375, 2014.
[29] M. Claussnitzer, S. N. Dankel, K.-H. Kim et al., “FTO obesity
variant circuitry and adipocyte browning in humans,”The New
England Journal of Medicine, vol. 373, pp. 895–907, 2015.
[30] A. Ragvin, E. Moro, D. Fredman et al., “Long-range gene
regulation links genomic type 2 diabetes and obesity risk
regions to HHEX, SOX4, and IRX3,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 107, no.
2, pp. 775–780, 2010.
6 International Journal of Endocrinology
[31] J. Fischer, L. Koch, C. Emmerling et al., “Inactivation of the Fto
gene protects from obesity,”Nature, vol. 458, no. 7240, pp. 894–
898, 2009.
[32] J. R. Speakman, “FTO effect on energy demand versus food
intake,” Nature, vol. 464, no. 7289, pp. E1–E2, 2010.
[33] F. McMurray, C. D. Church, R. Larder et al., “Adult onset global
loss of the Fto gene alters body composition and metabolism
in the mouse,” PLoS Genetics, vol. 9, no. 1, Article ID e1003166,
2013.
[34] C. Church, S. Lee, E. A. L. Bagg et al., “A mouse model for the
metabolic effects of the human fat mass and obesity associated
FTO gene,” PLoS Genetics, vol. 5, no. 8, Article ID e1000599,
2009.
[35] Y. C. L. Tung, P. Gulati, C.-H. Liu et al., “FTO is necessary for
the induction of leptin resistance by high-fat feeding,”Molecular
Metabolism, vol. 4, no. 4, pp. 287–298, 2015.
[36] X. Gao, Y.-H. Shin, M. Li, F. Wang, Q. Tong, and P. Zhang, “The
fat mass and obesity associated gene FTO functions in the brain
to regulate postnatal growth in mice,” PLoS ONE, vol. 5, no. 11,
Article ID e14005, 2010.
[37] C. Church, L. Moir, F. McMurray et al., “Overexpression of Fto
leads to increased food intake and results in obesity,” Nature
Genetics, vol. 42, no. 12, pp. 1086–1092, 2010.
[38] M. Merkestein, S. Laber, F. McMurray et al., “FTO influences
adipogenesis by regulating mitotic clonal expansion,” Nature
Communications, vol. 6, article 6792, 2015.
[39] J. Ronkainen, T. J. Huusko, R. Soininen et al., “Fat mass-
and obesity-associated gene Fto affects the dietary response in
mouse white adipose tissue,” Scientific Reports, vol. 5, article
9233, 2015.
[40] M. Arrizabalaga, E. Larrarte, J. Margareto, S. Maldonado-
Mart´ın, L. Barrenechea, and I. Labayen, “Preliminary findings
on the influence of FTO rs9939609 and MC4R rs17782313
polymorphisms on resting energy expenditure, leptin and thy-
rotropin levels in obese non-morbid premenopausal women,”
Journal of Physiology and Biochemistry, vol. 70, no. 1, pp. 255–
262, 2014.
[41] A. Shahid, S. Rana, S. Saeed, M. Imran, N. Afzal, and S.
Mahmood, “Common variant of FTO Gene, rs9939609, and
obesity in Pakistani females,” BioMed Research International,
vol. 2013, Article ID 324093, 7 pages, 2013.
[42] F. Rutters, A. G. Nieuwenhuizen, F. Bouwman, E. Mariman,
andM. S. Westerterp-Plantenga, “Associations between a single
nucleotide polymorphism of the FTO gene (rs9939609) and
obesity-related characteristics over time during puberty in a
Dutch children cohort,” The Journal of Clinical Endocrinology
& Metabolism, vol. 96, no. 6, pp. E939–E942, 2011.
[43] I. Labayen, J. R. Ruiz, F. B. Ortega et al., “Association between
the FTO rs9939609 polymorphism and leptin in European
adolescents: a possible link with energy balance control. the
HELENA study,” International Journal of Obesity, vol. 35, no. 1,
pp. 66–71, 2011.
[44] E. Zimmermann, K. Skogstrand, D. M. Hougaard et al., “Influ-
ences of the common FTO rs9939609 variant on inflammatory
markers throughout a broad range of body mass index,” PLoS
ONE, vol. 6, no. 1, Article ID e15958, 2011.
[45] L. Qi, K. Kang, C. Zhang et al., “Fatmass-and obesity-associated
(FTO) gene variant is associated with obesity: longitudinal
analyses in two cohort studies and functional test,”Diabetes, vol.
57, no. 11, pp. 3145–3151, 2008.
[46] R. Do, S. D. Bailey, K. Desbiens et al., “Genetic variants of FTO
influence adiposity, insulin sensitivity, leptin levels, and resting
metabolic rate in theQuebec Family Study,”Diabetes, vol. 57, no.
4, pp. 1147–1150, 2008.
[47] C. H. Andreasen, K. L. Stender-Petersen, M. S. Mogensen et
al., “Low physical activity accentuates the effect of the FTO
rs9939609 polymorphism on body fat accumulation,” Diabetes,
vol. 57, no. 1, pp. 95–101, 2008.
[48] C. Benedict, T. Axelsson, S. So¨derberg et al., “Fat mass and
obesity-associated gene (FTO) is linked to higher plasma levels
of the hunger hormone ghrelin and lower serum levels of the
satiety hormone leptin in older adults,” Diabetes, vol. 63, no. 11,
pp. 3955–3959, 2014.
[49] E. Karra, O. G. O’Daly, A. I. Choudhury et al., “A link between
FTO, ghrelin, and impaired brain food-cue responsivity,” The
Journal of Clinical Investigation, vol. 123, no. 8, pp. 3539–3551,
2013.
[50] X. T. Gan, G. Zhao, C. X. Huang, A. C. Rowe, D. M. Purdham,
and M. Karmazyn, “Identification of fat mass and obesity asso-
ciated (FTO) protein expression in cardiomyocytes: regulation
by leptin and its contribution to leptin-induced hypertrophy,”
PLoS ONE, vol. 8, no. 9, Article ID e74235, 2013.
[51] Y.-C. L. Tung, E. Ayuso, X. Shan et al., “Hypothalamic-specific
manipulation of Fto, the ortholog of the human obesity gene
FTO, affects food intake in rats,” PLoS ONE, vol. 5, no. 1, Article
ID e8771, 2010.
[52] P.Wang, F.-J. Yang, H. Du et al., “Involvement of leptin receptor
long isoform (LepRb)-STAT3 signaling pathway in brain fat
mass- and obesity-associated (FTO) downregulation during
energy restriction,”MolecularMedicine, vol. 17, no. 5-6, pp. 523–
532, 2011.
[53] A. Bravard, G. Vial, M.-A. Chauvin et al., “FTO contributes
to hepatic metabolism regulation through regulation of leptin
action and STAT3 signalling in liver,” Cell Communication and
Signaling, vol. 12, article 4, 2014.
[54] K. Ikels, S. Kuschel, J. Fischer et al., “FTO is a relevant factor
for the development of the metabolic syndrome in mice,” PLoS
ONE, vol. 9, no. 8, Article ID e105349, 2014.
[55] W. Ren, J. Guo, F. Jiang et al., “CCAAT/enhancer-binding
protein 𝛼 is a crucial regulator of human fat mass and obesity
associated gene transcription and expression,” BioMed Research
International, vol. 2014, Article ID 406909, 7 pages, 2014.
[56] F. Shao, X.Wang, J. Yu, H. Jiang, B. Zhu, and Z. Gu, “Expression
of miR-33 from an SREBF2 intron targets the FTO gene in the
chicken,” PLoS ONE, vol. 9, no. 3, Article ID e91236, 2014.
[57] A. Bravard,A.Veilleux, E.Disse et al., “The expression of FTO in
human adipose tissue is influenced by fat depot, adiposity, and
insulin sensitivity,” Obesity, vol. 21, no. 6, pp. 1165–1173, 2013.
[58] X. Zhao, Y. Yang, B.-F. Sun et al., “FTO-dependent demethy-
lation of N6-methyladenosine regulates mRNA splicing and is
required for adipogenesis,” Cell Research, vol. 24, no. 12, pp.
1403–1419, 2014.
[59] D. Tews, P. Fischer-Posovszky, and M. Wabitsch, “Regulation
of FTO and FTM expression during human preadipocyte
differentiation,” Hormone and Metabolic Research, vol. 43, no.
1, pp. 17–21, 2011.
[60] M. Zhang, Y. Zhang, J. Ma et al., “The demethylase activity of
FTO (fat mass and obesity associated protein) is required for
preadipocyte differentiation,” PLoS ONE, vol. 10, no. 7, Article
ID e0133788, 2015.
[61] X. Wang, L. Zhu, J. Chen, and Y. Wang, “mRNA m6A methy-
lation downregulates adipogenesis in porcine adipocytes,” Bio-
chemical and Biophysical Research Communications, vol. 459,
no. 2, pp. 201–207, 2015.
International Journal of Endocrinology 7
[62] E. Jeffery, C. D. Church, B. Holtrup, L. Colman, and M.
S. Rodeheffer, “Rapid depot-specific activation of adipocyte
precursor cells at the onset of obesity,” Nature Cell Biology, vol.
17, no. 4, pp. 376–385, 2015.
[63] T. Gerken, C. A. Girard, Y.-C. L. Tung et al., “The obesity-
associated FTO gene encodes a 2-oxoglutarate-dependent
nucleic acid demethylase,” Science, vol. 318, no. 5855, pp. 1469–
1472, 2007.
[64] G. Jia, Y. Fu, X. Zhao et al., “N6-methyladenosine in nuclear
RNA is amajor substrate of the obesity-associated FTO,”Nature
Chemical Biology, vol. 7, no. 12, pp. 885–887, 2011.
[65] J. J. Rochford, R. K. Semple, M. Laudes et al., “ETO/MTG8
is an inhibitor of C/EBP𝛽 activity and a regulator of early
adipogenesis,” Molecular and Cellular Biology, vol. 24, no. 22,
pp. 9863–9872, 2004.
[66] Q.Wu, R. A. Saunders,M. Szkudlarek-Mikho, I. de la Serna, and
K.-V. Chin, “The obesity-associated Fto gene is a transcriptional
coactivator,” Biochemical and Biophysical Research Communica-
tions, vol. 401, no. 3, pp. 390–395, 2010.
[67] D. Tews, P. Fischer-Posovszky, T. Fromme et al., “FTO defi-
ciency induces UCP-1 expression and mitochondrial uncou-
pling in adipocytes,” Endocrinology, vol. 154, no. 9, pp. 3141–3151,
2013.
[68] N. Witte, M. Muenzner, J. Rietscher et al., “The glucose sensor
ChREBP links de novo lipogenesis to PPAR𝛾 activity and
adipocyte differentiation,” Endocrinology, vol. 156, no. 11, pp.
4008–4019, 2015.
[69] R. Hardy, A. K. Wills, A. Wong et al., “Life course variations
in the associations between FTO and MC4R gene variants and
body size,” Human Molecular Genetics, vol. 19, no. 3, pp. 545–
552, 2009.
[70] P. Rzehak, A. Scherag, H. Grallert et al., “Associations between
BMI and the FTOgene are age dependent: results from theGINI
and LISA birth cohort studies up to age 6 years,” Obesity Facts,
vol. 3, no. 3, pp. 173–180, 2010.
[71] U. Sovio, D. O. Mook-Kanamori, N. M. Warrington et al.,
“Association between common variation at the FTO locus and
changes in body mass index from infancy to late childhood:
the complex nature of genetic association through growth and
development,” PLoS Genetics, vol. 7, no. 2, Article ID e1001307,
2011.
[72] V. Caruso, H. Chen, and M. J. Morris, “Early hypothalamic
fto overexpression in response to maternal obesity—potential
contribution to postweaning hyperphagia,” PLoS ONE, vol. 6,
no. 9, Article ID e25261, 2011.
[73] S. P. Se´bert, M. A. Hyatt, L. L. Y. Chan et al., “Influence of
prenatal nutrition and obesity on tissue specific fat mass and
obesity-associated (FTO) gene expression,” Reproduction, vol.
139, no. 1, pp. 265–274, 2009.
[74] C. G. Bell, S. Finer, C.M. Lindgren et al., “Integrated genetic and
epigenetic analysis identifies haplotype-specific methylation in
the FTO type 2 diabetes and obesity susceptibility locus,” PLoS
ONE, vol. 5, no. 11, Article ID e14040, 2010.
[75] X. Liu, A. Hinney, M. Scholz et al., “Indications for potential
parent-of-origin effects within the FTO gene,” PLoS ONE, vol.
10, no. 3, Article ID e0119206, 2015.
[76] Z. Zhang, D. Zhou, Y. Lai et al., “Estrogen induces endometrial
cancer cell proliferation and invasion by regulating the fat
mass and obesity-associated gene via PI3K/AKT and MAPK
signaling pathways,” Cancer Letters, vol. 319, no. 1, pp. 89–97,
2012.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
